Computer model predicts worsening cognitive scores, opening door to the use of machine learning in the selection of participants in Alzheimer’s disease trials.
Researchers show miniature livers can develop steatohepatitis and fibrosis, pointing to potential for personalized hepatic drug discovery and toxicity platforms.
Schrödinger secures further funding, extends collaboration with Morphic Therapeutic on computational discovery platform for oral integrin drugs for the second time.
Rinvoq from AbbVie to be available in the US in late August 2019, after receiving FDA approval for the treatment of adults with active rheumatoid arthritis.
Celgene’s Inrebic becomes the first treatment for myelofibrosis to be approved by the US FDA since 2011 after having received a priority review and orphan drug designation.
Nanoscale silica bottles, a five-hundredth of the diameter of a hair, could be used to deliver cancer drugs to specific disease sites in the body, avoiding debilitating side effects.
Researchers at the University of Illinois at Chicago reported that combining activated charcoal with herpes treatment acyclovir, improves the drug’s efficacy.
Intraprise Health creates the BluePrint Protect platform designed to solve cybersecurity challenges across the pharmaceutical supply chain as third-party data sharing accelerates.
Veeva Systems launches a software application aiming to reduce the time and effort of manual data entry, which will be integrated to its cloud-based suite.
Capital Health joins Kiyatec’s clinical trial to validate a patient-specific predictor test to improve response to cancer therapies for glioblastoma and anaplastic astrocytoma.
PCRF has selected Datavant to de-identify and link patient data across its clinical research network, which will ‘empower’ medical researchers while protecting patient privacy.
Frontage Clinical Services has expanded its site in New Jersey to accommodate nicotine-related studies and is developing a portfolio of assays to evaluate tobacco-specific biomarkers.
Engineered cardiac tissues generated using Tara Biosystems' heart-on-a-chip system predict how patients will respond to a range of drugs, as demonstrated in a recent study with GSK.
SGS’ OneVision initiative is working to standardize record-keeping across the global life sciences industry in an aim to accelerate laboratory testing, development, and eliminate paper-based systems.
FDA approves the third anti-TB drug in more than 40 years after the compound showed significantly higher success rates in patients with multi drug-resistant and extensively drug-resistant TB.
Iqvia today launches its new patient portal, designed to support clinical trial participants throughout the process with a “direct connection to the clinical research environment,” says company executive.
Medable joins the AHA’s ‘Innovators Network’ to develop the Human Heart Digitome, which is expected to be the largest real-world database dedicated to advancing cardiovascular disease research and patient care, says CEO.
After 2018 saw numerous sartan drugs recalled for possible carcinogenic impurities, in 2019, the industry kept an eye on the regulatory issues that followed and the breakthroughs that have mitigated some of the risks.
The increasing number of cell and gene therapies in clinical development is evolving the supply chain into a ‘supply cycle,’ says TrakCel CEO, with service providers being called to maintain control under pressure.
Almac bolsters its global clinical trial supply management and logistics offering – a market predicted to reach $26bn by 2024, according to a recent report.
The cell and gene therapy industry cannot grow without a ‘standardized, systematized, industrialized foundation,’ according to experts from Lonza and Vineti, which have teamed up to advance a ‘vein-to-vein’ delivery network.
The multi-stakeholder group is developing a blockchain-powered platform to increase transparency and collaboration in the clinical trial supply chain – and has successfully completed a proof-of-concept project, now looking to next steps.
The temperature-controlled logistics company expects demand to continue, with long-term plans to build out its bioservices operations – and a ‘revolutionary’ cryogenic storage system in the works.
Onconova to use Mission Bio’s Tapestri targeted single-cell DNA analysis platform to advance its cancer therapy, rigosertib, into Phase III clinical trials.
The clinical research site business, VitaLink Research, has acquired FL-based Comprehensive Clinical Trials, which conducts women’s health-focused Ph II-IV clinical trials.
Seres Therapeutics draws distinction between its quality practices and those of the fecal microbiota for transplantation (FMT) operations that triggered FDA alert.
Boehringer Ingelheim and the University of Texas MD Anderson Cancer Center entered a multi-year partnership to conduct collaborative translational research for lung and GI cancers.
Saama Technologies today announced that it has signed a definitive agreement to acquire Comprehend Systems, creating an ‘enhanced suite of complementary capabilities’ to ‘facilitate more rapid drug development,’ says company executives.
Cancer Research UK to support the clinical development of Hummingbird’s investigative cancer treatment which has the potential to fight drug resistant tumours.
Acclinate Genetics launches e-DICT, a clinical trials management system aiming to close the gap between the population rate of minorities in the US and their participation rate in clinical trials.
Through the combined offerings of WCG and PharmaSeek, the companies will be able to make a clinical trial site’s success both ‘predictable and achievable,’ says CEO.
Prellis advances its goal of using 3D holographic printing to create organoids for research and development – recently closing a $10.5m investment round to further develop its technology, which accelerates drug screening, says CEO.
Courts continue to rule in favor of Lilly’s lung cancer treatment patent, as the District Court for Appeals concludes generic producers like Dr Reddy’s to be potentially infringing.
The provider research models and services, BioIVT, has acquired Hatboro-PA-based Keystone Biologicals, which supplies disease-state plasma, sera, and controls.
Ever-expanding Clinerion adds another hospital to its Patient Network Explorer platform bringing clinical research to patients in Greece and expanding its client’s patient population coverage.
The Critical Path Institute and National Organization for Rare Disorders are developing a new data and analytics platform to inform clinical trial design and advance therapies for rare diseases.